STROBE and reporting observational studies in dermatology

DOI: 10.1111/j.1365-2133.2010.10136.x

The STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) initiative (http://www.strobe-statement.org/) is a recent major development about which all who undertake and report observational research in dermatology should be aware. The STROBE criteria aim to assess and improve the quality of reporting of epidemiological studies, but are not necessarily a measurement of the quality of the research. Clarity of reporting is a necessary criterion of judging study quality. For example, if a small poorly designed study is clearly reported as such, then at least readers will be able to see its shortcomings, as opposed to being left to guess what exactly was done in the study. One of the challenges authors of scientific articles face is to ensure that readers will understand what was planned, what was done, what the key findings were and what the results mean, so that the research can be interpreted appropriately.

In an international initiative, experts comprising methodologists, researchers and journal editors have, through an involved iterative process, developed clear guidance for authors on how to improve the quality of reporting of observational research. Specific checklists of essential items which should be reported for case–control, cohort and cross-sectional studies have been developed. Table 1 shows a combined STROBE checklist for reporting of these three types of studies. A recent extension of STROBE has been the development of STrengthening the REporting of Genetic Association studies (STREGA) to improve reporting of genetic epidemiological studies.

We recently studied the reporting of 183 observational studies that were published in five major dermatology journals between January 2005 and December 2007. Our focus was on the three study designs covered by a STROBE checklist. Assessment tools, modified from the STROBE checklists for cohort, case–control and cross-sectional studies, were piloted by members of the European Dermato-Epidemiology Network (EDEN) to clarify scoring and interpretation of the checklist items (http://eden.dermis.net/eden/content/e02eden/e01aims/e01programm/index_ger.html). Study articles were randomly allocated to pairs of reviewers and the assessment tools were used to determine the quality of reporting.

Areas where the reporting of observational dermatology studies was quite good (in more than 80% of articles) included reporting of key results in relation to study objectives detailing the scientific background and rationale for carrying out the study, summarizing the research in the abstract, and describing study objectives, design and outcomes. Significant areas of concern identified in the study included sample size calculations, description and management of missing data, details of losses to follow-up, statistical methods and the role of funders in the research.

Our survey of epidemiology studies from the dermatology literature underscores the need to improve the reporting of observational studies overall. Specifically, there is a need to focus on improving the reporting of the methods sections of such papers. These sections are critically important as they allow readers to determine whether bias and confounding may have impacted the study conclusions. Poor reporting limits the readers’ ability to assess the strengths and limitations of the data and to interpret and use the research findings appropriately. The latter includes secondary data analysis such as meta-analysis. It is also worth remembering the duty of researchers to give a faithful presentation of the results of their research in the public forum. The Helsinki Declaration emphasizes that authors, editors and publishers all have ethical obligations with regard to the publication of the results of research. ‘Authors have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports’ (Declaration of Helsinki: Basic Principles for all Medical Research).

Reporting guidelines have helped improve the quality of reporting of studies in the dermatology literature. For example, after the introduction of the Consolidated Standards for Reporting Trials (CONSORT) guidelines improvements in reporting of randomized controlled trials (RCTs) in dermatology were found. Adetugbo and Williams’ reported significant deficiencies in the reporting of RCTs in the dermatology literature between 1976 and 1997 and recommended the adoption of the CONSORT guidelines by dermatology journals. Alvarez et al. in 2009 reported an improvement in the reporting of dermatology RCTs in two selected journals between those published in 1997 and in 2006 after introduction of the CONSORT guidelines by those journals.

We believe the STROBE criteria are an excellent resource to guide authors, editors, peer reviewers and readers/users of the dermatology scientific literature. As from 1 January 2011, the BJD will request all authors submitting articles based on an observational study design to comply with the STROBE guidelines.

The BJD is proud of its tradition of publishing interesting and important epidemiological articles in the field of dermatology. Adoption of the STROBE guidelines can only serve to strengthen the quality of reporting and interpretability of such articles.
Table 1 STROBE statement: checklist of items that should be included in reports of observational studies

<table>
<thead>
<tr>
<th>Item no.</th>
<th>Recommendation</th>
</tr>
</thead>
</table>
| **Title and abstract** | 1 Indicate the study’s design with a commonly used term in the title or the abstract  
2 Provide in the abstract an informative and balanced summary of what was done and what was found |
| **Introduction** | 2 Explain the scientific background and rationale for the investigation being reported |
| **Objectives** | 3 State specific objectives, including any prespecified hypotheses |
| **Methods** | 4 Present key elements of study design early in the paper |
| **Study design** | 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection |
| **Participants** | 6 1 Cohort study – Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up  
2 Case–control study – Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls  
3 Cross-sectional study – Give the eligibility criteria, and the sources and methods of selection of participants |
| **Variables** | 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable |
| **Data sources/measurement** | 8a For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group |
| **Bias** | 9 Describe any efforts to address potential sources of bias |
| **Study size** | 10 Explain how the study size was arrived at |
| **Quantitative variables** | 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why |
| **Statistical methods** | 12 1 Describe all statistical methods, including those used to control for confounding  
2 Describe any methods used to examine subgroups and interactions  
3 Explain how missing data were addressed  
4 Cohort study – If applicable, explain how loss to follow-up was addressed  
Case–control study – If applicable, explain how matching of cases and controls was addressed  
Cross-sectional study – If applicable, describe analytical methods taking account of sampling strategy  
5 Describe any sensitivity analyses |
| **Results** | 13a 1 Report numbers of individuals at each stage of study – e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed  
2 Give reasons for nonparticipation at each stage  
3 Consider use of a flow diagram |
| **Descriptive data** | 14a 1 Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders  
2 Indicate number of participants with missing data for each variable of interest  
3 Cohort study – Summarize follow-up time (e.g. average and total amount) |
| **Outcome data** | 15a 1 Cohort study – Report numbers of outcome events or summary measures over time  
2 Case–control study – Report numbers in each exposure category, or summary measures of exposure  
3 Cross-sectional study – Report numbers of outcome events or summary measures |
| **Main results** | 16 1 Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g. 95% confidence interval). Make clear which confounders were adjusted for and why they were included  
2 Report category boundaries when continuous variables were categorized  
3 If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period |
| **Other analyses** | 17 Report other analyses done – e.g. analyses of subgroups and interactions, and sensitivity analyses |
| **Discussion** | 18 Summarize key results with reference to study objectives |
| **Limitations** | 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias |
| **Interpretation** | 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence |
| **Generalizability** | 21 Discuss the generalizability (external validity) of the study results |
| **Other information** | 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based |

*Give information separately for cases and controls in case–control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.*
Funding sources

Dr Langan is funded by fellowships from the British Association of Dermatologists and the National Psoriasis Foundation.

Conflicts of interest

None declared.

References

7 Adetugbo K, Williams HC. How well are randomized controlled trials reported in the dermatology literature? Arch Dermatol 2000; 136:381–5.